Fresenius Kabi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS KABI, and when can generic versions of FRESENIUS KABI drugs launch?
FRESENIUS KABI has three hundred and seven approved drugs.
There are twenty-three US patents protecting FRESENIUS KABI drugs. There are two tentative approvals on FRESENIUS KABI drugs.
There are one hundred and twenty-nine patent family members on FRESENIUS KABI drugs in twenty-five countries and four hundred and sixty-two supplementary protection certificates in seventeen countries.
Summary for Fresenius Kabi
International Patents: | 129 |
US Patents: | 23 |
Tradenames: | 248 |
Ingredients: | 185 |
NDAs: | 307 |
Patent Litigation for Fresenius Kabi: | See patent lawsuits for Fresenius Kabi |
PTAB Cases with Fresenius Kabi as petitioner: | See PTAB cases with Fresenius Kabi as petitioner |
PTAB Cases with Fresenius Kabi as patent owner: | See PTAB cases with Fresenius Kabi as patent owner |
Drugs and US Patents for Fresenius Kabi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | XYLOCAINE W/ EPINEPHRINE | epinephrine; lidocaine hydrochloride | INJECTABLE;INJECTION | 006488-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Fresenius Kabi Usa | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 077450-002 | Feb 10, 2006 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | CEFOTAXIME | cefotaxime sodium | INJECTABLE;INJECTION | 064200-003 | Mar 24, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Fresenius Kabi Usa | SODIUM CHLORIDE 3% IN PLASTIC CONTAINER | sodium chloride | INJECTABLE;INJECTION | 209476-001 | Mar 13, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | IOPAMIDOL-250 | iopamidol | INJECTABLE;INJECTION | 074679-001 | Apr 2, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Fresenius Kabi Usa | ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE | ondansetron hydrochloride | INJECTABLE;INJECTION | 076972-001 | Dec 26, 2006 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Kabi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-005 | Sep 24, 1996 | 4,695,576 | ⤷ Try a Trial |
Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-003 | May 1, 1998 | 5,834,489 | ⤷ Try a Trial |
Fresenius Kabi Usa | DILAUDID-HP | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-002 | Aug 4, 1994 | 6,589,960 | ⤷ Try a Trial |
Fresenius Kabi Usa | DILAUDID-HP | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-001 | Jan 11, 1984 | 6,589,960 | ⤷ Try a Trial |
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-004 | Apr 30, 2009 | 6,589,960 | ⤷ Try a Trial |
Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-005 | Sep 24, 1996 | 4,870,086 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS KABI drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2 mg, 4 mg, and 8 mg | ➤ Subscribe | 2013-08-05 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Injection | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | ➤ Subscribe | 2006-11-13 |
➤ Subscribe | Injection | 2 mg/mL, 200 mL | ➤ Subscribe | 2015-09-03 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | Injection | 2 mg/mL | ➤ Subscribe | 2011-06-22 |
➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2011-11-04 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL | ➤ Subscribe | 2015-01-30 |
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Oral Solution | 5 mg/5mL | ➤ Subscribe | 2011-02-25 |
International Patents for Fresenius Kabi Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1089080 | ⤷ Try a Trial |
San Marino | T201600452 | ⤷ Try a Trial |
Australia | 2004281535 | ⤷ Try a Trial |
Norway | 20062091 | ⤷ Try a Trial |
European Patent Office | 1507502 | ⤷ Try a Trial |
Hong Kong | 1085372 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Kabi Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2666774 | CA 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
1506193 | SPC/GB14/044 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RIOCIGUAT, I.E. METHYL N-(4,6-DIAMINO-2-(1-(2-FLUOROBENZYL)-1H-PYRAZOLO (3,4-B)PYRIDIN-3-YL)-5-PYRIMIDINYL(METHYL)CARBAMATE,OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE THEREOF.; REGISTERED: UK EU/1/13/907 20140331 |
0620232 | 01C0054 | France | ⤷ Try a Trial | PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024 |
2673237 | 1990016-6 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326 |
1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
2158901 | 122018000044 | Germany | ⤷ Try a Trial | PRODUCT NAME: AZTREONAMIYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.